Cargando…

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency

OBJECTIVE: The newly defined cancer-testis (CT) gene, MEIOB, was previously found to play key roles in DNA double-strand break (DSB) repair. In this study, we aimed to investigate the effects and mechanisms of MEIOB in the carcinogenesis of triple-negative breast cancers (TNBCs). METHODS: The Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Yayun, Wang, Cheng, Zhu, Rongxuan, Yang, Jianshui, Yuan, Wenwen, Zhu, Yanhui, Zhou, Yan, Qin, Na, Shen, Hongbing, Ma, Hongxia, Wang, Hongxia, Liu, Xiaoan, Hu, Zhibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877187/ https://www.ncbi.nlm.nih.gov/pubmed/33628586 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0071

Ejemplares similares

MEIOB Targets Single-Strand DNA and Is Necessary for Meiotic Recombination
por: Souquet, Benoit, et al.
Publicado: (2013)

MEIOB exhibits single-stranded DNA-binding and exonuclease activities and is essential for meiotic recombination
por: Luo, Mengcheng, et al.
Publicado: (2013)

The ssDNA-binding protein MEIOB acts as a dosage-sensitive regulator of meiotic recombination
por: Guo, Rui, et al.
Publicado: (2020)

Genetic variants in regulatory regions of microRNAs are associated with lung cancer risk
por: Xie, Kaipeng, et al.
Publicado: (2016)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

Systematic identification of long non-coding RNAs with cancer-testis expression patterns in 14 cancer types
por: Qin, Na, et al.
Publicado: (2017)

Nuclear localization of human MEIOB requires its NLS in the OB domain and interaction with SPATA22: Human SPATA22 assists MEIOB to enter the nucleus
por: Xu, Yating, et al.
Publicado: (2022)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types
por: Wang, Cheng, et al.
Publicado: (2016)

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
por: Zhu, Ying, et al.
Publicado: (2023)

Novel MEIOB variants cause primary ovarian insufficiency and non-obstructive azoospermia
por: Wang, Yurong, et al.
Publicado: (2022)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Cancer‐testis gene PIWIL1 promotes cell proliferation, migration, and invasion in lung adenocarcinoma
por: Xie, Kaipeng, et al.
Publicado: (2017)

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
por: Yin, Chao, et al.
Publicado: (2022)

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Peng, Yihan, et al.
Publicado: (2019)

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
por: Wang, Junhui, et al.
Publicado: (2015)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer
por: Yadav, Anjali, et al.
Publicado: (2023)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
por: Schoonen, Pepijn M., et al.
Publicado: (2017)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells
por: Wang, Hongge, et al.
Publicado: (2020)

Genetic Variants in the Promoter Region of miR-10b and the Risk of Breast Cancer
por: Chen, Jiaping, et al.
Publicado: (2017)

Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency
por: Liao, Gaoming, et al.
Publicado: (2022)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
por: Zhang, Ning, et al.
Publicado: (2021)

Comprehensive characterization of cancer‐testis genes in testicular germ cell tumor
por: Chang, Yuting, et al.
Publicado: (2019)

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
por: Amin, Oreekha, et al.
Publicado: (2015)

Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
por: Pai Bellare, Ganesh, et al.
Publicado: (2021)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival
por: Xie, Tao, et al.
Publicado: (2022)

Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention
por: Wang, Yuzhuo, et al.
Publicado: (2022)

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
por: Sugimura, Kazuto, et al.
Publicado: (2008)

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
por: Beck, Carole, et al.
Publicado: (2014)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
por: Lahiguera, Álvaro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i93h1hoa40mc8unqedmt62g0fg